CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
Jitske van den BulkManon van der PloegMarieke E IjsselsteijnDina RuanoRuud van der BreggenRebekka DuhenKoen C M J PeetersArantza Fariña-SarasquetaElizabeth M E VerdegaalSjoerd H van der BurgThomas DuhenNoel F C C de MirandaPublished in: Journal for immunotherapy of cancer (2023)
T cells in MMR-proficient CRCs with low mutation burden. The exploitation of these subsets in the context of adoptive T cell transfer or engineered T cell receptor therapies is a promising avenue to extend the benefits of immunotherapy to an increasing number of CRC patients.